LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
Filed an 8-K today reporting results of operations · per SEC
Sources: SEC
From SEC filing · Not investment advice
Filed an 8-K today reporting results of operations · per SEC
From the company’s SEC filing: what was filed, no summary.
Sources: SEC
Written 6:00 PM ET · last check 7:30 PM ET
From SEC filing · Not investment adviceSign up free to see this.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Votes and Bull · Bear posts, 24h. At least 5 are needed.
How do you feel about LMAT?
GlobeNewswire Inc.
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026LeMaitre Vascular, Inc. announced it will release its third quarter 2026 financial results on November 4, 2026, after market close, followed by a conference call at 5:00 PM EST to discuss results, business highlights, and company outlook.
Headlines open the publisher's site.
$LMAT filed an 8-K with results (Item 2.02) at 4:40 PM ET on Wed, Nov 4.
Community opinions, not advice. Posts with a target get a receipt. How receipts work ›
